Arginine is preferred to glucagon for stimulation testing of β-cell function

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 8, 2014, Pages E720-E727

  Robertson, R Paul ^a   Raymond, Ralph H ^b   Lee, Douglas S ^c   Calle, Roberto A ^c   Ghosh, Atalanta ^d   Savage, Peter J ^e   Shankar, Sudha S ^f   Vassileva, Maria T ^g   Weir, Gordon C ^h   Fryburg, David A ⁱ  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b R Squared Solutions   (United States)

^c 3Pfizer Incorporated   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h JOSLIN DIABETES CENTER   (United States)

ⁱ ROI BioPharma Consulting   (United States)

Author keywords

Arginine; Glucagon; Insulin secretion; cell function

Indexed keywords

ARGININE; C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL RESEARCH; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIET RESTRICTION; DIZZINESS; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL PARESTHESIA; PANCREAS ISLET BETA CELL; PROVOCATION TEST; SEX DIFFERENCE; ANALYSIS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC USE; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; METABOLISM; MIDDLE AGED; MOUTH MUCOSA; PARESTHESIA; PATHOPHYSIOLOGY; REPRODUCIBILITY; SECRETION (PROCESS);

ADULT; AGED; ARGININE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; FEMALE; GLUCAGON; HUMANS; HYPERGLYCEMIA; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN-SECRETING CELLS; KINETICS; MALE; MIDDLE AGED; MOUTH MUCOSA; NAUSEA; OBESITY; PARESTHESIA; REPRODUCIBILITY OF RESULTS;

EID: 84908052749     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00149.2014     Document Type: Article

References (40)

1. Ahrén B, Nobin A, Scherstén B. Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships. Acta Med Scand 221: 185-190, 1987.
2. Beattie GM, Otonkoski T, Lopez AD, Hayek A. Functional beta-cell mass after transplantation of human fetal pancreatic cells: differentiation or proliferation? Diabetes 46: 244-248, 1997.
3. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D, Jr. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42: 222-229, 1976.
4. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53: 1187-1194, 2004.
5. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 10: 93-102, 1994.
6. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med 12: 144-148, 2006.
7. Faradji RN, Monroy K, Messinger S, Pileggi A, Froud T, Baidal DA, Cure PE, Ricordi C, Luzi L, Alejandro R. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 7: 303-308, 2007.
8. Henquin JC. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in beta-cells. Diabetes Res Clin Pract 93, Suppl 1: S27-S31, 2011.
9. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, Ysebaert D, Roep B, Vandemeulebroucke E, Marichal M, In 't Veld P, Bogdani M, Hendrieckx C, Gorus F, Ling Z, van Rood J, Pipeleers D. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA 103: 17444-17449, 2006.
10. Koch GG. Intraclass correlation coefficient. In: Encyclopedia of Statistical Sciences 4, edited by Kotz S and Johnson NL. New York: John Wiley & Sons, 1982, p. 213-217.
11. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. Am J Physiol Endocrinol Metab 305: E1398-E1407, 2013.
12. Larsen MO, Rolin B, Sturis J, Wilken M, Carr RD, Pørksen N, Gotfredsen CF. Measurements of insulin responses as predictive markers of pancreatic β-cell mass in normal and β-cell-reduced lean and obese Göttingen minipigs in vivo. Am J Physiol Endocrinol Metab 290: E670-E677, 2006.
13. Larsson H, Ahrén B. Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11: 201-205, 1995.
14. Larsson H, Ahrén B. Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia 41: 772-777, 1998.
15. Leahy JL, Bonner-Weir S, Weir GC. Abnormal glucose regulation of insulin secretion in models of reduced B-cell mass. Diabetes 33: 667-673, 1984.
16. Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, Holz GG. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol 107: 236-247, 2011.
17. Liu Z, Jeppesen PB, Gregersen S, Chen X, Hermansen K. Dose-and Glucose-Dependent Effects of Amino Acids on Insulin Secretion from Isolated Mouse Islets and Clonal INS-1E Beta-Cells. Rev Diabet Stud 5: 232-244, 2009.
18. Matveyenko AV, Veldhuis JD, Butler PC. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 55: 2347-2356, 2006.
19. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP. Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 40: 673-679, 1991.
20. Miki H, Matsuyama T, Fujii S, Komatsu R, Nishioeda Y, Omae T. Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes. Diabetes Res Clin Pract 18: 99-105, 1992.
21. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, Schuit F. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 47: 66-72, 1998.
22. Montana E, Bonner-Weir S, Weir GC. Transplanted beta cell response to increased metabolic demand. Changes in beta cell replication and mass. J Clin Invest 93: 1577-1582, 1994.
23. Palmer JP, Benson JW, Walter RM, Ensinck JW. Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest 58: 565-570, 1976.
24. Robertson RP. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes 53: 633-644, 2004.
25. Robertson RP. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 56: 2420-2424, 2007.
26. Robertson RP, Lanz KJ, Sutherland DE, Kendall DM. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 50: 47-50, 2001.
27. Ronnemaa T. Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Lab Invest 46: 345-349, 1986.
28. Sarlund H, Laakso M, Pyorala K, Penttila I. Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in noninsulin-dependent diabetics and in control subjects. Acta Med Scand 221: 377-383, 1987.
29. Sarlund H, Siitonen O, Laakso M, Pyorala K. Repeatability of C-peptide response in glucagon stimulation test. Acta Endocrinol (Copenh) 114: 515-518, 1987.
30. Scheen AJ, Castillo MJ, Lefebvre PJ. Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement. Diabetes Metab 22: 455-458, 1996.
31. Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 22: 397-406, 1996.
32. Snorgaard O, Hasselstrøm K, Lumholtz IB, Thorsteinsson B, Siersbaek-Nielsen K. Insulin/C-peptide response to intravenous glucagon. A dose-response study in normal and non-insulin-dependent diabetic subjects. Acta Endocrinol (Copenh) 117: 109-115, 1988.
33. Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, Kilbourn M, Goland R, Leibel R, Mann JJ, Van Heertum R, Harris PE. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116: 1506-1513, 2006.
34. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47: 324-330, 1998.
35. Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 43: 593-598, 1994.
36. Tobin BW, Lewis JT, Chen DZ, Finegood DT. Insulin secretory function in relation to transplanted islet mass in STZ-induced diabetic rats. Diabetes 42: 98-105, 1993.
37. Vague P, Nguyen L. Rationale and methods for the estimation of insulin secretion in a given patient: from research to clinical practice. Diabetes 51, Suppl 1: S240-S244, 2002.
38. van Haeften TW, Boonstra E, Veneman TF, Gerich JE, van der Veen EA. Dose-response characteristics for glucose-stimulated insulin release in man and assessment of influence of glucose on arginine-stimulated insulin release. Metabolism 39: 1292-1299, 1990.
39. Wang T, Xiao XH, Li WH, Wang H, Sun Q, Yuan T, Yang GH. Effects of glucagon on islet beta cell function in patients with diabetes mellitus. Chin Med Sci J 23: 117-120, 2008.
40. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760, 2008.